NIH/Biosite Licensing Agreement Proposed For Atherosclerosis Gene Markers
This article was originally published in The Gray Sheet
Executive Summary
Biosite is contemplating exclusively licensing genetic markers from the National Institutes of Health for the early diagnosis of coronary artery disease
You may also be interested in...
Biosite On Track To Earn First Rapid Stroke Assay Approval With PMA Filing
Biosite expects to present data comparing its Triage Stroke Panel to computed axial tomography (CAT) to FDA's Clinical Chemistry & Toxicology Devices Panel this year
NEJM Study Deems CRP Significant, Compared With Other Cardiac Markers
A recent New England Journal of Medicine study identifying C-reactive protein as a significant marker of coronary heart disease risk may prove to be a boon for CRP diagnostic manufacturers
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.